Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Nishant Shah

Preventive Cardiology · Duke Hospital

View

Dr. Amit Khera

Preventive Cardiology · UT Southwestern

View

Dr. Martha Gulati

Preventive Cardiology · Houston Methodist

View

Dr. Pradeep Natarajan

Preventive Cardiology · MGH

View

Dr. Christopher Cannon

Preventive Cardiology · BWH

View

Dr. Nicholas Marston

Preventive Cardiology · BWH

View

Dr. Dorairaj Prabhakaran

General Cardiology

View

Dr. Pugazhendhi Vijayaraman

EP · Geisinger

View

Dr. Robert Schaller

EP · HUP

View

Dr. Trey Woods

General Cardiology · Emory Healthcare

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    JLDr. J. Antonio Lopez

    Dr. J. Antonio Lopez

    Cardiology · Preventive Cardiology
    Amgen (United States)
    jantonio
    Camarillo, CA, USA

    Research

    Lp(a) Has Specific Effects on Coronary Artery Disease Independent of LDL-C: A Mendelian Randomization Study

    2026

    Via JACC Adv

    Research

    Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition: A Prespecified Analysis From FOURIER

    2026

    Via J Am Coll Cardiol

    Research

    Abstract 4369532: Estimated absolute coronary heart disease risk reduction with Lp(a) lowering among adults with atherosclerotic cardiovascular disease

    2025

    Via Circulation

    Research

    Heterogeneity of Apolipoprotein B Levels Among Hispanic or Latino Individuals Residing in the US

    2025

    Via JAMA Cardiol

    Research

    Intraindividual Variability in Serial Lipoprotein(a) Concentrations Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial

    2025

    Via J Am Coll Cardiol

    Research

    Olpasiran lowering of lipoprotein(a) according to baseline levels: insights from the OCEAN(a)-DOSE study

    2025

    Via Eur Heart J

    Research

    Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial

    2025

    Via JAMA Cardiol

    Research

    Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial

    2025

    Via Diabetes Care

    Research

    Association of Lp(a) With Cardiovascular Disease and All-Cause Mortality in U.S. Hispanics and Latinos

    2025

    Via J Am Coll Cardiol

    Research

    Small-Interfering RNA Olpasiran and Apolipoprotein B Particles

    2025

    Via JAMA Cardiol

    Research

    Quantification of LDL-Cholesterol Corrected for Molar Concentration of Lipoprotein(a)

    2024

    Via Cardiovasc Drugs Ther

    Research

    Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease

    2024

    Via J Am Coll Cardiol

    Research

    Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease

    2024

    Via J Am Coll Cardiol

    Mar 28, 2024Journal Article

    Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.

    ​

    Written by 1 Roon author & 10 others

    Via The American Heart Association Journals

    Research

    Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE

    2023

    Via Circulation